The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 25, 2022

Filed:

Oct. 10, 2018
Applicant:

Tilos Therapeutics, Inc., Lexington, MA (US);

Inventors:

Barbara S. Fox, Wayland, MA (US);

Randall Burton, Billerica, MA (US);

Stavros Kopsiaftis, West Roxbury, MA (US);

Xiufeng Song, Jamaica Plain, MA (US);

Patricia Rao, Acton, MA (US);

Kenneth J. Simon, Milton, MA (US);

Jessie M. English, Cambridge, MA (US);

Assignee:

Tilos Therapeutics, Inc., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 16/22 (2006.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61K 9/0019 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6851 (2017.08); A61K 47/6879 (2017.08); A61K 47/6887 (2017.08); A61P 35/00 (2018.01); C07K 16/22 (2013.01); C07K 16/2827 (2013.01); C07K 16/2839 (2013.01); C07K 16/30 (2013.01); G01N 33/574 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/54 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); G01N 2800/52 (2013.01);
Abstract

Provided herein are antibodies which bind to latency-associated peptide (LAP) of TGF-β1 and are characterized by particular functional features, such as binding specifically to LAP-TGFβ1 on cells but not to LAP-TGFβ1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.


Find Patent Forward Citations

Loading…